A unique bone graft substitute material developed by Biocomposites has been approved for human use by the U.S. Food and Drug Administration. The privately held British firm has its North American sales headquarters in Wilmington, N.C.
The product, geneX putty, is a resorbable bone graft material that stimulates bone cell activity, accelerating bone formation by harnessing key proteins and directing the healing process where it's needed.
"By exploiting our unparalleled expertise in synthetic calcium composite technology," said Biocomposites president Stephen Bratt, "we have developed a new class of biomaterial, which represents a significant advance in bone grafting options for the surgeon."
The release of geneX putty adds to Biocomposites' family of synthetic bone grafts, which includes a previously FDA-cleared geneX paste and an injectable setting matrix. All the products are engineered with the firm's negatively charged surface chemistry.